Crosstalk Between the Insulin-like Growth Factors and Estrogens in Breast Cancer

Overview

Journal J Mammary Gland Biol Neoplasia

Date 2000 May 3

PMID 10791773

Citations 65

Authors

D Yee

A V Lee

Affiliations

Soon will be listed here.

Abstract

Once it was recognized that breast tumor growth was stimulated by estrogens, successful therapeutic strategies based on depriving the tumor of this hormone were developed. Since the growth stimulatory properties of the estrogens are governed by the estrogen receptor (ER), understanding the mechanisms that activate ER are highly relevant. In addition to estrogens, peptide growth factors can also activate the ER. The insulin-like growth factors (IGFs) are potent mitogens for ER-positive breast cancer cell lines. This review will examine the evidence for interaction between these two pathways. The IGFs can activate the ER, while ER transcriptionally regulates genes required for IGF action. Moreover, blockade of ER function can inhibit IGF-mediated mitogenesis and interruption of IGF action can similarly inhibit estrogenic stimulation of breast cancer cells. Taken together, these observations suggest that the two growth regulatory pathways are tightly linked and that a further understanding of the mechanism of this crosstalk could lead to new therapeutic strategies in breast cancer.

Citing Articles

Canine Mammary Tumors: Classification, Biomarkers, Traditional and Personalized Therapies.

Nosalova N, Huniadi M, Hornakova L, Valencakova A, Hornak S, Nagoos K Int J Mol Sci. 2024; 25(5).

PMID: 38474142 PMC: 10931591. DOI: 10.3390/ijms25052891.

Estrogen Receptor-β Agonists Modulate T-Lymphocyte Activation and Ameliorate Left Ventricular Remodeling During Chronic Heart Failure.

Rosenzweig R, Kumar V, Gupta S, Bermeo-Blanco O, Stratton M, Gumina R Circ Heart Fail. 2022; 15(7):e008997.

PMID: 35730443 PMC: 9308745. DOI: 10.1161/CIRCHEARTFAILURE.121.008997.

Loss of E-cadherin Induces IGF1R Activation and Reveals a Targetable Pathway in Invasive Lobular Breast Carcinoma.

Elangovan A, Hooda J, Savariau L, Puthanmadhomnarayanan S, Yates M, Chen J Mol Cancer Res. 2022; 20(9):1405-1419.

PMID: 35665642 PMC: 9444924. DOI: 10.1158/1541-7786.MCR-22-0090.

BRCA1: An Endocrine and Metabolic Regulator.

Werner H Front Endocrinol (Lausanne). 2022; 13:844575.

PMID: 35432218 PMC: 9009035. DOI: 10.3389/fendo.2022.844575.

A Role for ER-Beta in the Effects of Low-Density Lipoprotein Cholesterol and 27-Hydroxycholesterol on Breast Cancer Progression: Involvement of the IGF Signalling Pathway?.

Mashat R, Zielinska H, Holly J, Perks C Cells. 2022; 11(1).

PMID: 35011656 PMC: 8749996. DOI: 10.3390/cells11010094.

References

Lee A, Jackson J, Gooch J, Hilsenbeck S, Osborne C, Yee D . Enhancement of insulin-like growth factor signaling in human breast cancer: estrogen regulation of insulin receptor substrate-1 expression in vitro and in vivo. Mol Endocrinol. 1999; 13(5):787-96. DOI: 10.1210/mend.13.5.0274. View

McCotter D, van den Berg H, Boylan M, Mckibben B . Changes in insulin-like growth factor-I receptor expression and binding protein secretion associated with tamoxifen resistance and estrogen independence in human breast cancer cells in vitro. Cancer Lett. 1996; 99(2):239-45. DOI: 10.1016/0304-3835(95)04104-4. View

Daly R, Harris W, Wang D, Darbre P . Autocrine production of insulin-like growth factor II using an inducible expression system results in reduced estrogen sensitivity of MCF-7 human breast cancer cells. Cell Growth Differ. 1991; 2(9):457-64. View

Sell C, Dumenil G, Deveaud C, Miura M, Coppola D, DeAngelis T . Effect of a null mutation of the insulin-like growth factor I receptor gene on growth and transformation of mouse embryo fibroblasts. Mol Cell Biol. 1994; 14(6):3604-12. PMC: 358728. DOI: 10.1128/mcb.14.6.3604-3612.1994. View

Van den Berg C, Cox G, Stroh C, Hilsenbeck S, Weng C, McDermott M . Polyethylene glycol conjugated insulin-like growth factor binding protein-1 (IGFBP-1) inhibits growth of breast cancer in athymic mice. Eur J Cancer. 1997; 33(7):1108-13. DOI: 10.1016/s0959-8049(97)00071-3. View

Rocha R, Hilsenbeck S, Jackson J, VanDenBerg C, Weng C, Lee A . Insulin-like growth factor binding protein-3 and insulin receptor substrate-1 in breast cancer: correlation with clinical parameters and disease-free survival. Clin Cancer Res. 1997; 3(1):103-9. View

Figueroa J, Jackson J, McGuire W, Krywicki R, Yee D . Expression of insulin-like growth factor binding proteins in human breast cancer correlates with estrogen receptor status. J Cell Biochem. 1993; 52(2):196-205. DOI: 10.1002/jcb.240520211. View

Kato S, Endoh H, Masuhiro Y, Kitamoto T, Uchiyama S, Sasaki H . Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science. 1995; 270(5241):1491-4. DOI: 10.1126/science.270.5241.1491. View

Tremblay G, Tremblay A, Copeland N, Gilbert D, Jenkins N, Labrie F . Cloning, chromosomal localization, and functional analysis of the murine estrogen receptor beta. Mol Endocrinol. 1997; 11(3):353-65. DOI: 10.1210/mend.11.3.9902. View

10.

Webb P, Nguyen P, SHINSAKO J, Anderson C, Feng W, Nguyen M . Estrogen receptor activation function 1 works by binding p160 coactivator proteins. Mol Endocrinol. 1998; 12(10):1605-18. DOI: 10.1210/mend.12.10.0185. View

11.

Yee D, Cullen K, Paik S, Perdue J, Hampton B, Schwartz A . Insulin-like growth factor II mRNA expression in human breast cancer. Cancer Res. 1988; 48(23):6691-6. View

12.

Pollak M . Endocrine effects of IGF-I on normal and transformed breast epithelial cells: potential relevance to strategies for breast cancer treatment and prevention. Breast Cancer Res Treat. 1998; 47(3):209-17. DOI: 10.1023/a:1005950916707. View

13.

El-Tanani M, GREEN C . Two separate mechanisms for ligand-independent activation of the estrogen receptor. Mol Endocrinol. 1997; 11(7):928-37. DOI: 10.1210/mend.11.7.9939. View

14.

Ruan W, Catanese V, Wieczorek R, Feldman M, Kleinberg D . Estradiol enhances the stimulatory effect of insulin-like growth factor-I (IGF-I) on mammary development and growth hormone-induced IGF-I messenger ribonucleic acid. Endocrinology. 1995; 136(3):1296-302. DOI: 10.1210/endo.136.3.7867584. View

15.

Figueroa J, Sharma J, Jackson J, McDermott M, Hilsenbeck S, Yee D . Recombinant insulin-like growth factor binding protein-1 inhibits IGF-I, serum, and estrogen-dependent growth of MCF-7 human breast cancer cells. J Cell Physiol. 1993; 157(2):229-36. DOI: 10.1002/jcp.1041570204. View

16.

Yang X, Beamer W, Huynh H, Pollak M . Reduced growth of human breast cancer xenografts in hosts homozygous for the lit mutation. Cancer Res. 1996; 56(7):1509-11. View

17.

Kuiper G, Enmark E, Pelto-Huikko M, Nilsson S, Gustafsson J . Cloning of a novel receptor expressed in rat prostate and ovary. Proc Natl Acad Sci U S A. 1996; 93(12):5925-30. PMC: 39164. DOI: 10.1073/pnas.93.12.5925. View

18.

Huynh H, Yang X, Pollak M . Estradiol and antiestrogens regulate a growth inhibitory insulin-like growth factor binding protein 3 autocrine loop in human breast cancer cells. J Biol Chem. 1996; 271(2):1016-21. DOI: 10.1074/jbc.271.2.1016. View

19.

McMahon C, Suthiphongchai T, DiRenzo J, Ewen M . P/CAF associates with cyclin D1 and potentiates its activation of the estrogen receptor. Proc Natl Acad Sci U S A. 1999; 96(10):5382-7. PMC: 21868. DOI: 10.1073/pnas.96.10.5382. View

20.

Pimentel M, Parker M, McLachlan J, Korach K . Peptide growth factor cross-talk with the estrogen receptor requires the A/B domain and occurs independently of protein kinase C or estradiol. Endocrinology. 1996; 137(5):1735-44. DOI: 10.1210/endo.137.5.8612509. View